DNA Script Honored by Goldman Sachs for Entrepreneurship
sylvain-gariel
PARIS and SOUTH SAN FRANCISCO, Calif. | October 14, 2020

Sylvain Gariel, COO, Among 100 Most Intriguing Entrepreneurs at 2020 Builders + Innovators Summit

DNA Script today announced Goldman Sachs (NYSE:GS) is recognizing Chief Operations Officer and Co-Founder Sylvain Gariel as one of the 100 Most Intriguing Entrepreneurs of 2020 at its Builders + Innovators Summit.

Goldman Sachs selected Sylvain Gariel as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. He co-founded DNA Script in 2014 with Thomas Ybert and Xavier Godron. Sylvain coinvented DNA Script’s core technology of Enzymatic DNA Synthesis (EDS), which powers the first product of the company, SYNTAX™. With SYNTAX™, DNA Script aims at bringing DNA synthesis to the lab bench to enable scientists unprecedented speed and autonomy. The current pandemic illustrates the need for speed and control in the context of new diagnostic, vaccine or drug development. In the long run, DNA Script’s upcoming product portfolio will enable personalized medicine. Awardee of the MIT Innovator Under 35 2017, Sylvain played an instrumental role in building a French American team of 75 based in Paris and San Francisco and in raising over $140 million in equity and non-dilutive financing.

“We cofounded DNA Script with a simple idea: offering to the life science community access to synthetic DNA right at the bench with unprecedented speed, control and quality. Our goal has never changed: enable better and faster insights into human biology and ultimately better care for patients. We believe our system SYNTAX™is a first step in that direction. I am tremendously excited Goldman Sachs has recognized the value and potential of our approach” said Sylvain Gariel, COO and Co-Founder of DNA Script.

In addition to honoring 100 entrepreneurs, the summit, which this year will take place virtually, consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.